Loading clinical trials...
Loading clinical trials...
The current Standard of Care (SOC) for chronic HCV infection, which is pegylated interferon-alfa as combination therapy with ribavirin for 24-48 weeks of treatment, is effective in only part of the pa...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boehringer Ingelheim
NCT07052162 · Pharmacokinetics of Tafenoquine
NCT06953479 · HEPATITIS C (HCV), Incarceration, and more
NCT04961593 · Pharmacokinetics, Infection, Fungal
NCT02456974 · Pharmacokinetics, Amoxicillin-clavulanate, and more
NCT06426836 · Pharmacokinetics, Amoxicillin-clavulanate, and more
1220.14.003 Boehringer Ingelheim Investigational Site
Kurashiki, Okayama
1220.14.001 Boehringer Ingelheim Investigational Site
Minato-ku, Tokyo
1220.14.002 Boehringer Ingelheim Investigational Site
Nishinomiya, Hyogo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions